James Lyski - 01 May 2025 Form 4 Insider Report for CARMAX INC (KMX)

Reporting relationship: EVP, Chief Growth & Strat Off
Issuer ticker: KMX
Reported as of: 01 May 2025
Net transaction value: -$96,329
SEC form: 4
Accepted by SEC: 05 May 2025, 16:11:07 UTC
Prior SEC filing: 11 Apr 2025
Source filing: View source filing
Reporting owner signature: Christine Carter, attorney-in-fact

Key filing fact

James Lyski filed Form 4 for CARMAX INC (KMX) on 05 May 2025.

Key facts

This page summarizes James Lyski's Form 4 filing for CARMAX INC (KMX).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 05 May 2025, 16:11.

Change

Previous filing in this sequence was filed on 11 Apr 2025.
Current net transaction value: -$96,329.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001376853 Primary reporting owner

Lyski James

Relationship: EVP, Chief Growth & Strat Off
Address: 12800 TUCKAHOE CREEK PARKWAY, RICHMOND
Signature: Christine Carter, attorney-in-fact
Signature date: 05 May 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

KMX transaction

Common Stock

Tax liability

Transaction value: $96,329
Shares: -1,444
Change %: -5%
Price: $66.71
Shares after: 27,164
Date: 02 May 2025
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

KMX transaction Derivative

Stock Options (Right to Buy)

Award

Transaction value: $0
Shares: +38,124
Change %
Price: $0.000000
Shares after: 38,124
Date: 01 May 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 38,124
Exercise price: $65.52
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The stock options were granted in tandem with stock appreciation rights (SARS). Accordingly, the exercise of one results in the surrender to the Company of the other. The SARS become exercisable only following a change in control of the Company as set forth in the Company's 2002 Stock Incentive Plan, as amended and restated. Once exercisable, the SARS would entitle the Reporting Person to receive the cash value of the options in lieu of exercising the options.

Footnote F2

The stock options become exercisable with respect to one-fourth of the underlying shares of Common Stock on each of May 1, 2026, May 1, 2027, May 1, 2028 and May 1, 2029.